Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 13/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 13/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547648 | 0.82 | SRD5A2 (0.43) | MAPTHPGD | |
| SCHEMBL25400667 | 0.81 | FNTA (0.47) | MAT2AMAPTHPGD | |
| SCHEMBL26301906 | 0.80 | BAZ2B (0.49) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL26301942 | 0.79 | BAZ2B (0.51) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL30676989 | 0.79 | MAPT (0.43) | ALDH1A1MAPTHPGD | |
| SCHEMBL25400578 | 0.78 | BAZ2B (0.45) | BAZ2BBAZ2ABRD4BRD9BRD2 | |
| SCHEMBL26301924 | 0.78 | BAZ2B (0.47) | BAZ2BBAZ2ABRD4BRD9MAT2A | |
| SCHEMBL29547188 | 0.78 | ALDH1A1 (0.40) | ALDH1A1MAPT | |
| SCHEMBL29547156 | 0.76 | L3MBTL1 (0.36) | ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL26301954 | 0.75 | BAZ2B (0.49) | BAZ2BBAZ2ABRD9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233864-B1 | COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4233864-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | Ajou University Industry-Academic Cooperation Foundation (KR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022086260-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | 아주대학교산학협력단 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | STING1, IRF3, IFNG | BAZ2B 4487/4885BAZ2A 4020/4885BRD4 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.